Sensorion Has Presented an Abstract on Recovering Hearing Loss at the Neuroscience 2015 …

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN / PEA-PME eligible), a biotech specialising in the treatment of inner ear diseases, today announces that the results of a preclinical trial on a new drug candidate aimed at the curative treatment of severe hearing loss have been presented at the Society for Neuroscience’s 45thannual meeting (Neuroscience 2015) in Chicago. The abstract, entitled “Effective protection against severe noise-induced hearing loss by a small molecule clinical drug candidate following daily, post-trauma systemic administration”, was presented during a session devoted to mechanoreceptors and the cochlea by Dr. Jonas Dyhrfjeld-Johnsen, Sensorion’s Head of Pharmacology. Sensorion carried out a proof-of-concept in vivo preclinical trial on animals affected by acute bilateral neurosensory hearing loss. In this study, animals were exposed to a 120 dB noise level…


Link to Full Article: Sensorion Has Presented an Abstract on Recovering Hearing Loss at the Neuroscience 2015 …